Ottani F, Galvani M, Ferrini D, Sorbello F, Limonetti P, Pantoli D, Rusticali F
Divisione di Cardiologia and Fondazione Cardiologica M.Z. Sacco, Ospedale G.B. Morgagni, Forli, Italy.
Circulation. 1995 Jan 15;91(2):291-7. doi: 10.1161/01.cir.91.2.291.
In the experimental setting, it has been demonstrated that preconditioning myocardium before prolonged occlusion with brief ischemic episodes affords substantial protection to the cells by delaying lethal injury, thereby limiting infarct size. Whether the same occurs in humans remains unknown.
This study was undertaken to determine whether new-onset prodromal angina, defined as chest pain episodes limited to the 24 hours before myocardial infarction, is the clinical correlate of the ischemic preconditioning phenomenon. Twenty-five patients with their first anterior myocardial infarction treated with thrombolysis (recombinant tissue plasminogen activator [r-TPA], 100 mg/3 hours) were retrospectively included in the study because they met the following criteria: (1) < 120 minutes from onset of symptoms to reperfusion therapy, (2) < 90 minutes from the beginning of thrombolytic therapy to reperfusion (defined as rapid ST elevation reduction > 50%), (3) a patient infarct-related coronary artery with TIMI 3 flow and complete absence of collateral circulation to the infarct related artery (assessed at 24 +/- 5 days), and (4) the presence of new-onset prodromal angina, ie, typical chest pain episodes occurring at rest within 24 hours or, alternatively, a complete absence of symptoms before onset of infarction. Therefore, on the basis of their clinical status before infarction, the patients were divided into two groups: group 1, 13 patients without prodromal angina, and group 2, 12 patients with prodromal angina. Despite no difference in time to treatment (81 +/- 19 versus 75 +/- 21 minutes in group 1 and group 2, respectively; P = NS) and time to reperfusion (58 +/- 34 versus 46 +/- 24 minutes; P = NS), the peak of CKMB release was markedly lower in group 2 (86.3 +/- 66 versus 192.3 +/- 108.3 IU/L; P < .01). In addition, although both groups were comparable in terms of area at risk (amount of myocardium beyond the infarct-related stenosis; 15.1 +/- 4.6 versus 13.7 +/- 4.6 hypokinetic segments in group 1 and group 2, respectively, P = NS), the final infarct size (11 +/- 7.5 versus 5.6 +/- 4 hypokinetic segments, P < .04) was smaller in group 2. Thus, the limitation of the infarct size was significantly greater in group 2 (69% versus 36%; P < .05), and this represents an additional 33% reduction (95% confidence intervals, 7.1% to 58.9%; P = .01) in the group of patients with prodromal angina. Also, the third index, that is, the ECG, showed a favorable trend toward a lesser number of Q waves and a higher sigma R waves, although the values did not reach statistical significance.
Despite a similar area at risk, patients with new-onset prodromal angina showed a significantly smaller infarct size compared with patients without prodromal symptoms. Since the two groups had similar times to reperfusion and no evidence of collateral circulation to the infarct related artery, the protection afforded by angina in group 2 patients might be explained by the occurrence of ischemic preconditioning.
在实验环境中,已证实通过短暂缺血发作对心肌进行预处理,在长时间闭塞之前可通过延迟致命性损伤为细胞提供实质性保护,从而限制梗死面积。这在人类中是否同样发生尚不清楚。
本研究旨在确定新发前驱性心绞痛(定义为心肌梗死前24小时内出现的胸痛发作)是否为缺血预处理现象的临床相关表现。25例首次发生前壁心肌梗死并接受溶栓治疗(重组组织型纤溶酶原激活剂[r-TPA],100mg/3小时)的患者因符合以下标准而被回顾性纳入研究:(1)症状发作至再灌注治疗时间<120分钟;(2)溶栓治疗开始至再灌注时间<90分钟(定义为ST段抬高快速降低>50%);(3)患者梗死相关冠状动脉TIMI 3级血流且梗死相关动脉完全无侧支循环(在24±5天评估);(4)存在新发前驱性心绞痛,即梗死前24小时内静息时出现典型胸痛发作,或者梗死发作前完全无症状。因此,根据梗死前的临床状态,将患者分为两组:第1组,13例无前驱性心绞痛患者;第2组,12例有前驱性心绞痛患者。尽管两组在治疗时间(第1组和第2组分别为81±19分钟和75±21分钟;P=无显著性差异)和再灌注时间(58±34分钟和46±24分钟;P=无显著性差异)上无差异,但第2组CKMB释放峰值明显较低(86.3±66与192.3±108.3 IU/L;P<.01)。此外,尽管两组在危险区域面积(梗死相关狭窄以外的心肌量)方面具有可比性(第1组和第2组分别为15.1±4.6和13.7±4.6运动减弱节段,P=无显著性差异),但第2组最终梗死面积较小(11±7.5与5.6±4运动减弱节段,P<.04)。因此,第2组梗死面积的限制明显更大(69%对36%;P<.05),这意味着有前驱性心绞痛的患者组额外减少了33%(95%置信区间,7.1%至58.9%;P=.01)。同样,第三个指标即心电图显示出Q波数量较少和R波总和较高的有利趋势,尽管这些值未达到统计学显著性。
尽管危险区域面积相似,但与无前驱症状的患者相比,新发前驱性心绞痛患者的梗死面积明显较小。由于两组再灌注时间相似且梗死相关动脉无侧支循环证据,第2组患者中心绞痛提供的保护可能由缺血预处理的发生来解释。